Skip to main content
    R

    Revolution Medicines Inc (RVMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $166.87
    -5.42 (-3.15%)

    Market Cap: $37.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Revolution Medicines Inc (RVMD) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Revolution Medicines reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$1.13B, operating cash flow was -$897.74M and free cash flow was -$913.73M. The quarter ended Sep 30, 2026 had revenue of $197.56M and net income of -$407.46M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $1.18B.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$11.58M-67.3%100.0%-4207.1%-3768.3%
    Dec 2022$35.38M+20.4%100.0%-730.0%-703.0%
    Dec 2021$29.39M-31.6%100.0%-639.7%-636.6%
    Dec 2020$42.98M-14.1%100.0%-257.5%-251.6%
    Dec 2019$50.04M+148.2%100.0%-108.2%-95.2%
    Dec 2018$20.16MN/A100.0%-200.0%-207.2%
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$0$0$11.58M$35.38M$29.39M$42.98M$50.04M$20.16M$0
    Cost of revenue$0$0$0$0$0$0$0$0$26.59M
    Gross profit$0$0$11.58M$35.38M$29.39M$42.98M$50.04M$20.16M-$26.59M
    Research and development$987.33M$592.23M$423.14M$253.07M$186.95M$132.25M$91.75M$51.08M$26.59M
    Operating income-$1.18B-$689.52M-$487.19M-$258.28M-$188.01M-$110.70M-$54.12M-$40.33M-$31.13M
    Net income-$1.13B-$600.09M-$436.37M-$248.71M-$187.09M-$108.16M-$47.66M-$41.79M-$31.13M
    EBITDAN/AN/AN/A-$251.70M-$177.68M-$103.18M-$51.23MN/A-$29.84M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$197.56M$0$0$0$0$0$0$261.59M$0$0$0$742.00K
    Gross profit$197.23M$0$0-$4.70M$0$0$0-$188.10M$0$0$0$742.00K
    Operating income-$373.15M-$505.13M-$445.22M-$361.63M-$315.27M-$264.71M-$240.76M-$216.31M-$175.71M-$156.64M-$140.86M-$179.98M
    Net income-$407.46M-$644.37M-$453.82M-$364.89M-$305.21M-$247.79M-$213.42M-$194.57M-$156.29M-$133.23M-$116.00M-$161.54M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $16.47M by $367.28M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$2.35B$2.56B$2.06B$811.93M$737.99M$567.40M$220.53M$170.59M$15.08M
    Current assets$2.08B$2.33B$1.88B$660.18M$589.77M$454.12M$133.98M$85.43M$9.44M
    Cash and equivalents$383.75M$543.06M$696.15M$161.41M$108.50M$104.27M$16.66M$69.59M$9.08M
    Total liabilities$723.21M$293.10M$235.51M$126.74M$135.42M$92.72M$67.99M$73.93M$10.55M
    Short-term debt$16.47M$12.87M$7.37M$6.77M$6.21M$3.67M$200.00K$147.00KN/A
    Shareholder equity$1.63B$2.27B$1.83B$685.19M$602.57M$474.68M-$152.57M$96.66M$4.53M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$4.30B$4.32B$2.25B$2.35B$2.25B$2.43B$2.37B$2.56B$1.76B$1.81B$1.91B$2.06B
    Total liabilities$1.90B$1.72B$753.82M$723.21M$655.02M$564.20M$287.20M$293.10M$196.69M$189.59M$182.90M$235.51M
    Cash and equivalents$615.91M$815.43M$440.94M$383.75M$217.44M$402.44M$333.55M$543.06M$201.26M$275.71M$288.43M$696.15M
    Shareholder equity$2.40B$2.61B$1.50B$1.63B$1.60B$1.87B$2.08B$2.27B$1.57B$1.62B$1.73B$1.83B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$897.74M-$557.44M-$350.57M-$224.40M-$147.18M-$100.06M-$49.62M$1.21M-$25.15M
    Capital expenditures$15.99M$10.31M$7.73M$10.82M$6.53M$2.93M$2.59M$1.50M$1.57M
    Free cash flow-$913.73M-$567.74M-$358.30M-$235.22M-$153.71M-$103.00M-$52.20M-$286.00K-$26.72M
    Investing cash flow$118.06M-$554.39M-$342.60M-$24.12M-$142.12M-$234.23M-$101.97M-$1.34M-$1.57M
    Financing cash flow$621.52M$959.41M$1.23B$301.43M$294.18M$422.78M$98.66M$60.85M$22.66M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$415.65M-$387.32M-$354.17M-$274.24M-$207.31M-$221.76M-$194.44M-$138.29M-$130.42M-$128.17M-$160.56M-$120.56M
    Capital expenditures$3.70M$2.29M$1.54M$1.93M$3.35M$7.45M$3.27M$1.22M$3.52M$2.40M$3.17M$2.32M
    Free cash flow-$419.35M-$389.61M-$355.70M-$276.16M-$210.66M-$229.21M-$197.70M-$139.51M-$133.94M-$130.57M-$163.73M-$122.88M
    Last 12 quarters

    Frequently Asked Questions About RVMD

    What is Revolution Medicines' annual revenue?

    Revolution Medicines reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Revolution Medicines profitable?

    No. Revolution Medicines reported net income of -$1.13B for the fiscal year ended Dec 31, 2025.

    How much free cash flow does RVMD generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$897.74M minus capital expenditures of $15.99M produced free cash flow of -$913.73M.

    How much debt does Revolution Medicines have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $16.47M and cash and equivalents of $383.75M.